文献速递核素与放射性配体治疗肿瘤 PET/CT

[123I]CC1:一种靶向PARP、发射俄歇电子的放射性药物用于癌症放射性核素治疗

[123I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.
PubMed 文献 · J Nucl Med · 2023-12-01

本研究报道了一种123I标记的PARP抑制剂[123I]CC1,用于癌症的放射性配体治疗。体外和体内实验显示[123I]CC1在乳腺癌、胰腺腺癌和胶质母细胞瘤模型中具有选择性摄取,低至10 Bq即可显著降低克隆形成能力,静脉注射3 MBq可显著抑制PSN1异种移植瘤生长,且对正常组织未见显著毒性。结论提示[123I]CC1作为靶向PARP表达癌症的放射性配体治疗具有潜力。

要点

  • [123I]CC1在乳腺癌、胰腺腺癌和胶质母细胞瘤细胞及异种移植瘤模型中均显示选择性摄取。
  • 体外低至10 Bq的[123I]CC1即可显著降低克隆形成能力。
  • 静脉注射3 MBq [123I]CC1可显著抑制PSN1异种移植瘤生长,对PARP表达较低的异种移植瘤效果较差,且未对正常组织造成显著毒性。

核心结论

  • 结果表明[123I]CC1作为靶向PARP表达癌症的放射性配体治疗具有潜力。

研究设计与样本

  • 本研究为临床前体外和体内研究,使用人乳腺癌、胰腺腺癌和胶质母细胞瘤细胞,以及小鼠荷人癌异种移植瘤(MDA-MB-231、PSN1和U87MG)模型。

主要发现

  • 体外和体内研究显示[123I]CC1在所有模型中均具有选择性摄取。
  • 体外经低至10 Bq [123I]CC1处理后观察到克隆形成能力显著降低。
  • 静脉给药后1小时生物分布显示PSN1肿瘤异种移植瘤摄取为0.9 ± 0.06 每克组织注射剂量百分比。
  • 静脉注射相对低量的[123I]CC1(3 MBq)能够显著抑制PSN1异种移植瘤生长,但在PARP表达较低的异种移植瘤中效果较差。
  • [123I]CC1未对正常组织引起显著毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Poly(adenosine diphosphate ribose) polymerase (PARP) has emerged as an effective therapeutic strategy against cancer that targets the DNA damage repair enzyme. PARP-targeting compounds radiolabeled with an Auger electron-emitting radionuclide can be trapped close to damaged DNA in tumor tissue, where high ionizing potential and short range lead Auger electrons to kill cancer cells through the creation of complex DNA damage, with minimal damage to surrounding normal tissue. Here, we report on [123I]CC1, an 123I-labeled PARP inhibitor for radioligand therapy of cancer. Methods: Copper-mediated 123I iododeboronation of a boronic pinacol ester precursor afforded [123I]CC1. The level and specificity of cell uptake and the therapeutic efficacy of [123I]CC1 were determined in human breast carcinoma, pancreatic adenocarcinoma, and glioblastoma cells. Tumor uptake and tumor growth inhibition of [123I]CC1 were assessed in mice bearing human cancer xenografts (MDA-MB-231, PSN1, and U87MG). Results: In vitro and in vivo studies showed selective uptake of [123I]CC1 in all models. Significantly reduced clonogenicity, a proxy for tumor growth inhibition by ionizing radiation in vivo, was observed in vitro after treatment with as little as 10 Bq [123I]CC1. Biodistribution at 1 h after intravenous administration showed PSN1 tumor xenograft uptake of 0.9 ± 0.06 percentage injected dose per gram of tissue. Intravenous administration of a relatively low amount of [123I]CC1 (3 MBq) was able to significantly inhibit PSN1 xenograft tumor growth but was less effective in xenografts that expressed less PARP. [123I]CC1 did not cause significant toxicity to normal tissues. Conclusion: Taken together, these results show the potential of [123I]CC1 as a radioligand therapy for PARP-expressing cancers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chan CY, Chen Z, Guibbal F, et al. [123I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer. J Nucl Med. 2023. PMID: 37770109. doi:10.2967/jnumed.123.265429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。